Calliditas Therapeutics AB
STO:CALTX

Watchlist Manager

Calliditas Therapeutics AB

STO:CALTX

Watchlist

Dividends

Price: 208 SEK 0.87%

Market Cap: 12.5B SEK

Have any thoughts about
Calliditas Therapeutics AB?

Write Note

Write Note Create Alert Ask AI

Add Note Why Create Notes?

Capture your thoughts

Note Buy Sell Hold Pass

US	Johnson & Johnson NYSE:JNJ	Pharmaceuticals
US	Berkshire Hathaway Inc NYSE:BRK.A	Financial Services
US	Bank of America Corp NYSE:BAC	Banking
US	Mastercard Inc NYSE:MA	Technology
US	UnitedHealth Group Inc NYSE:UNH	Health Care
US	Exxon Mobil Corp NYSE:XOM	Energy
US	Pfizer Inc NYSE:PFE	Pharmaceuticals
US	Palantir Technologies Inc NYSE:PLTR	Technology
US	Nike Inc NYSE:NKE	Textiles, Apparel & Luxury Goods
US	Visa Inc NYSE:V	Technology
CN	Alibaba Group Holding Ltd NYSE:BABA	Retail
US	3M Co NYSE:MMM	Industrial Conglomerates
US	JPMorgan Chase & Co NYSE:JPM	Banking
US	Coca-Cola Co NYSE:KO	Beverages
US	Walmart Inc NYSE:WMT	Retail
US	Verizon Communications Inc NYSE:VZ	Telecommunication

Add Price Alert

Price Target:

Last Price: 208 SEK

We'll email you a reminder when the closing price reaches USD.

If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.

Peter Lynch

Track and Analyze Performance

Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.

Continuous Learning and Adaptation

Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.

Boost Decision Confidence

With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.

Why create notes?

Back

Delete Note

Do you really want to delete this note?
This action cannot be undone.

Remove price alert for reaching

Delete

Cancel

CALTX Alert

Calliditas Therapeutics AB

208

+1.8 (+0.87%)

52 Week Range	91.1 208.2
Price Target

We'll email you a reminder when the closing price reaches SEK.

Save Alert

Choose the stock you wish to monitor with a price alert.

	Johnson & Johnson NYSE:JNJ	US
	Berkshire Hathaway Inc NYSE:BRK.A	US
	Bank of America Corp NYSE:BAC	US
	Mastercard Inc NYSE:MA	US
	UnitedHealth Group Inc NYSE:UNH	US
	Exxon Mobil Corp NYSE:XOM	US
	Pfizer Inc NYSE:PFE	US
	Palantir Technologies Inc NYSE:PLTR	US
	Nike Inc NYSE:NKE	US
	Visa Inc NYSE:V	US
	Alibaba Group Holding Ltd NYSE:BABA	CN
	3M Co NYSE:MMM	US
	JPMorgan Chase & Co NYSE:JPM	US
	Coca-Cola Co NYSE:KO	US
	Walmart Inc NYSE:WMT	US
	Verizon Communications Inc NYSE:VZ	US

Delete Alert

This alert will be permanently deleted.

Remove note

Delete

Cancel

Ask me anything about

Calliditas Therapeutics AB

What unique competitive advantages
does Calliditas Therapeutics AB hold over its rivals?

What risks and challenges
does Calliditas Therapeutics AB face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Provide an overview of the primary business activities
of Calliditas Therapeutics AB.

What unique competitive advantages
does Calliditas Therapeutics AB hold over its rivals?

What risks and challenges
does Calliditas Therapeutics AB face in the near future?

Has there been any significant insider trading activity
in Calliditas Therapeutics AB recently?

Summarize the latest earnings call
of Calliditas Therapeutics AB.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Calliditas Therapeutics AB.

Provide P/S
for Calliditas Therapeutics AB.

Provide P/E
for Calliditas Therapeutics AB.

Provide P/OCF
for Calliditas Therapeutics AB.

Provide P/FCFE
for Calliditas Therapeutics AB.

Provide P/B
for Calliditas Therapeutics AB.

Provide EV/S
for Calliditas Therapeutics AB.

Provide EV/GP
for Calliditas Therapeutics AB.

Provide EV/EBITDA
for Calliditas Therapeutics AB.

Provide EV/EBIT
for Calliditas Therapeutics AB.

Provide EV/OCF
for Calliditas Therapeutics AB.

Provide EV/FCFF
for Calliditas Therapeutics AB.

Provide EV/IC
for Calliditas Therapeutics AB.

Show me price targets
for Calliditas Therapeutics AB made by professional analysts.

What are the Revenue projections
for Calliditas Therapeutics AB?

How accurate were the past Revenue estimates
for Calliditas Therapeutics AB?

What are the Net Income projections
for Calliditas Therapeutics AB?

How accurate were the past Net Income estimates
for Calliditas Therapeutics AB?

What are the EPS projections
for Calliditas Therapeutics AB?

How accurate were the past EPS estimates
for Calliditas Therapeutics AB?

What are the EBIT projections
for Calliditas Therapeutics AB?

How accurate were the past EBIT estimates
for Calliditas Therapeutics AB?

Compare the revenue forecasts
for Calliditas Therapeutics AB with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Calliditas Therapeutics AB and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Calliditas Therapeutics AB against its competitors.

Analyze the profit margins
(gross, operating, and net) of Calliditas Therapeutics AB compared to its peers.

Compare the P/E ratios
of Calliditas Therapeutics AB against its peers.

Discuss the investment returns and shareholder value creation
comparing Calliditas Therapeutics AB with its peers.

Analyze the financial leverage
of Calliditas Therapeutics AB compared to its main competitors.

Show all profitability ratios
for Calliditas Therapeutics AB.

Provide ROE
for Calliditas Therapeutics AB.

Provide ROA
for Calliditas Therapeutics AB.

Provide ROIC
for Calliditas Therapeutics AB.

Provide ROCE
for Calliditas Therapeutics AB.

Provide Gross Margin
for Calliditas Therapeutics AB.

Provide Operating Margin
for Calliditas Therapeutics AB.

Provide Net Margin
for Calliditas Therapeutics AB.

Provide FCF Margin
for Calliditas Therapeutics AB.

Show all solvency ratios
for Calliditas Therapeutics AB.

Provide D/E Ratio
for Calliditas Therapeutics AB.

Provide D/A Ratio
for Calliditas Therapeutics AB.

Provide Interest Coverage Ratio
for Calliditas Therapeutics AB.

Provide Altman Z-Score Ratio
for Calliditas Therapeutics AB.

Provide Quick Ratio
for Calliditas Therapeutics AB.

Provide Current Ratio
for Calliditas Therapeutics AB.

Provide Cash Ratio
for Calliditas Therapeutics AB.

What is the historical Revenue growth
over the last 5 years for Calliditas Therapeutics AB?

What is the historical Net Income growth
over the last 5 years for Calliditas Therapeutics AB?

What is the current Free Cash Flow
of Calliditas Therapeutics AB?

Discuss the annual earnings per share (EPS)
trend over the past five years for Calliditas Therapeutics AB.

P/FCFE
Price to FCFE

-76

Current

-21.6

Median

23.6

Industry

Lower than median

Lower than industry value

Price to Free Cash Flow To Equity (P/FCFE) ratio is a valuation multiple that compares a company’s market capitalization to the amount of free cash flow available for equity shareholders. This metric is very similar to the P/OCF but is considered a more exact measure, owing to the fact that it uses free cash flow, which subtracts capital expenditures (CapEx) from a company's operating cash flow.

P/FCFE

-76

Market Cap

12.5B SEK

FCFE

-164.1m SEK

All Countries

Forward Multiples

			Market Cap	P/FCFE
SE		Calliditas Therapeutics AB STO:CALTX	12.5B SEK	-76
JP	N	Nichi-Iko Pharmaceutical Co Ltd TSE:4541	776 550.9T JPY	-40 845 137.7
US		Eli Lilly and Co NYSE:LLY	749.7B USD	91.7
UK		Dechra Pharmaceuticals PLC LSE:DPH	440.4B GBP	2 143.3
DK		Novo Nordisk A/S CSE:NOVO B	3.3T DKK	34.7
US		Johnson & Johnson NYSE:JNJ	372B USD	12.8
US		Merck & Co Inc NYSE:MRK	257.3B USD	15.5
CH		Roche Holding AG SIX:ROG	200.6B CHF	20.1
UK		AstraZeneca PLC LSE:AZN	162.5B GBP	22.5
CH		Novartis AG SIX:NOVN	179.9B CHF	11.7
US		Pfizer Inc NYSE:PFE	146B USD	25.5


SE		Calliditas Therapeutics AB STO:CALTX	Average P/FCFE: 264.2 Negative Multiple: -76
JP	N	Nichi-Iko Pharmaceutical Co Ltd TSE:4541	Negative Multiple: -40 845 137.7
US		Eli Lilly and Co NYSE:LLY	91.7
UK		Dechra Pharmaceuticals PLC LSE:DPH	2 143.3
DK		Novo Nordisk A/S CSE:NOVO B	34.7
US		Johnson & Johnson NYSE:JNJ	12.8
US		Merck & Co Inc NYSE:MRK	15.5
CH		Roche Holding AG SIX:ROG	20.1
UK		AstraZeneca PLC LSE:AZN	22.5
CH		Novartis AG SIX:NOVN	11.7
US		Pfizer Inc NYSE:PFE	25.5

P/FCFE Forward Multiples

Forward P/FCFE multiple is a version of the P/FCFE ratio that uses forecasted free cash flow to equity for the P/FCFE calculation. 1-Year, 2-Years, and 3-Years forwards use free cash flow to equity forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward

P/FCFE

N/A

2-Years Forward

P/FCFE

N/A

3-Years Forward

P/FCFE

N/A

Calliditas Therapeutics AB
STO:CALTX

P/FCFE
Price to FCFE

P/FCFE Forward Multiples

See Also

Company

Help

Tools

Stocks

Calliditas Therapeutics AB STO:CALTX

P/FCFE Price to FCFE

P/FCFE Forward Multiples

See Also

Company

Help

Tools

Stocks

Calliditas Therapeutics AB
STO:CALTX

P/FCFE
Price to FCFE